Overview

Safety Study of AZD5672 in Renally Impaired Subjects

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to investigate the pharmacokinetics of a single dose of AZD5672 in patients with renal impairment by comparing with healthy volunteers

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide